MedPath

Ketotifen

Generic Name
Ketotifen
Brand Names
Alaway, Zaditen, Zaditor
Drug Type
Small Molecule
Chemical Formula
C19H19NOS
CAS Number
34580-13-7
Unique Ingredient Identifier
X49220T18G

Overview

Ketotifen is a benzocycloheptathiophene derivative with potent antihistaminic and mast cell stabilizing properties. It has a similar structure to some other first-generation antihistamines such as cyproheptadine and azatadine. Ketotifen was first developed in Switzerland in 1970 by Sandoz Pharmaceuticals and was initially marketed for the treatment of anaphylaxis. In the US, it is now used in an over-the-counter ophthalmic formulation for the treatment of itchy eyes associated with allergies, and in Canada a prescription-only oral formulation is available and indicated as an add-on therapy for children with atopic asthma. In addition, oral ketotifen is used in Mexico and across Europe for the treatment of various allergic symptoms and disorders, including urticaria, mastocytosis, and food allergy.

Background

Ketotifen is a benzocycloheptathiophene derivative with potent antihistaminic and mast cell stabilizing properties. It has a similar structure to some other first-generation antihistamines such as cyproheptadine and azatadine. Ketotifen was first developed in Switzerland in 1970 by Sandoz Pharmaceuticals and was initially marketed for the treatment of anaphylaxis. In the US, it is now used in an over-the-counter ophthalmic formulation for the treatment of itchy eyes associated with allergies, and in Canada a prescription-only oral formulation is available and indicated as an add-on therapy for children with atopic asthma. In addition, oral ketotifen is used in Mexico and across Europe for the treatment of various allergic symptoms and disorders, including urticaria, mastocytosis, and food allergy.

Indication

Administered orally, ketotifen is indicated as an add-on medication in the chronic treatment of mild atopic asthma in children. It is also available as an over-the-counter ophthalmic solution which is indicated for the temporary prevention of itching of the eye due to allergic conjunctivitis.

Associated Conditions

  • Allergic Rhinitis (AR)
  • Asthma, Allergic
  • Eye pruritus
  • Seasonal Allergic Conjunctivitis

Research Report

Published: Apr 30, 2025

Comprehensive Report: Ketotifen

I. Introduction and Drug Identification

  • A. Overview of Ketotifen Ketotifen is a pharmaceutical agent recognized for its utility in managing various allergic conditions. Its therapeutic action stems from a dual mechanism, functioning both as a histamine H1 receptor antagonist (antihistamine) and as a mast cell stabilizer.3 This combination of activities allows it to address different facets of the allergic response. The drug is available in multiple formulations tailored for specific applications. Ophthalmic preparations, including eye drops and, more recently, drug-eluting contact lenses, are primarily employed for the symptomatic relief of allergic conjunctivitis, targeting ocular itching and irritation.3 Oral formulations, such as tablets and syrups, are utilized systemically for the prophylaxis of mild atopic asthma, particularly in pediatric populations in certain regions, and for the management of other allergic-type disorders.3
  • B. Chemical Properties Ketotifen belongs to the benzocycloheptathiophene class of compounds.4 Chemically, the base form is identified as 4-(1-Methyl-4-piperidinylidene)-4,9-dihydro-10H-benzo1cyclohepta[1,2-b]thiophen-10-one.2 However, it is frequently formulated and administered as its hydrogen fumarate salt.5 The IUPAC name for the base is 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one 4, while the fumarate salt is named (E)-but-2-enedioic acid;2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one.7 Variations in nomenclature exist across sources.4 The molecular formula for the ketotifen base is C19​H19​NOS [1], with a corresponding molecular weight of approximately 309.43 g/mol.[1] The fumarate salt has the molecular formula C23​H23​NO5​S and a molecular weight of 425.50 g/mol.[5] The distinction between the base and the salt form is critical,

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2022/11/21
Phase 3
Recruiting
2022/11/15
Phase 4
Not yet recruiting
2022/10/24
Phase 3
Completed
2022/08/23
Phase 4
Not yet recruiting
2020/06/17
N/A
Completed
Horus University
2020/05/22
Not Applicable
Completed
2018/07/10
Phase 3
Completed
2018/04/06
Phase 3
Completed
2018/03/27
Phase 3
Completed
2016/12/06
Phase 3
Completed
McGill University Health Centre/Research Institute of the McGill University Health Centre

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Johnson & Johnson Vision Care, Inc.
60123-019
INTRAOCULAR
0.019 mg in 1 1
2/28/2022

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
SUNTOTIFEN SYRUP 1 mg/5 ml
SIN08053P
SYRUP
1 mg/5 ml
2/28/1995
KETOTIFEN SYRUP 1 mg/5 ml
SIN08766P
SYRUP
1 mg/5 ml
7/3/1996
DHATIFEN TABLET 1 mg
SIN07601P
TABLET
1 mg
1/5/1994
ZADITEN EYE DROPS 0.25 mg/ml
SIN12209P
SOLUTION
0.25 mg/ml
2/25/2003
TOFEN TABLET 1 mg
SIN09651P
TABLET
1 mg
2/17/1998
ZADITEN SYRUP 1 mg/5 ml (sugar-free)
SIN07573P
SYRUP
1 mg/5 ml
12/15/1993
ASMAFEN SYRUP 1 mg/5 ml
SIN08831P
SYRUP
1 mg/5 ml
8/6/1996
SUNTOTIFEN TABLET 1 mg
SIN08054P
TABLET
1 mg
2/28/1995
AXCEL KETOTIFEN SYRUP 1 mg/5 ml
SIN10544P
SYRUP
1 mg/5 ml
12/12/1998
ASUMALIFE SYRUP 1 mg/5 ml
SIN10107P
SYRUP
1 mg/5 ml
9/17/1998

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Ketotifun Fumarate Aerosol for Nasal
国药准字H20044219
化学药品
气雾剂
7/13/2020
Ketotifun Fumarate Aerosol for Nasal
国药准字H31022604
化学药品
气雾剂
8/5/2020
Ketotifen Fumarate Capsules
国药准字H31020513
化学药品
胶囊剂
4/9/2020
Ketotifen Fumarate Capsules
国药准字H46020232
化学药品
胶囊剂
3/24/2020
Ketotifen Fumarate Capsules
国药准字H31021308
化学药品
胶囊剂
4/9/2020
Ketotifen Fumarate Capsules
国药准字H13020461
化学药品
胶囊剂
9/9/2020
Ketotifen Fumarate Capsules
国药准字H33020916
化学药品
胶囊剂
8/15/2024
Ketotifen Fumarate Capsules
国药准字H11021234
化学药品
胶囊剂
11/27/2020
Ketotifen Fumarate Capsules
国药准字H44022431
化学药品
胶囊剂
4/1/2020
Ketotifen Fumarate Capsules
国药准字H44020041
化学药品
胶囊剂
4/9/2020

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath